George Tachas
drug
University of Leeds
Brazil
Biography
Dr George Tachas is Director Drug Discovery and Patents at Antisense Therapeutics Ltd, a Melbourne Australia based company listed on the Australian Stock Exchange (ASX). He is an immunologist and molecular biologist with a PhD (1988) and a Diploma of Intellectual Property law (1994) both from the University of Melbourne. After postdoctoral studies (1991) he worked for Australian patent firms Griffith Hack and Co. (1994) and Callinan Lawrie (1997). Dr Tachas then planned to start up an antisense company, designed antisense inhibitors, contracted and funded drug manufacture and animal pharmacology studies and licensed his technology to Syngene Ltd. This led to Dr Tachas becoming an exclusive consultant to Antisense Therapeutics (2000) and founding Research Director when Circadian Technologies listed the company on the ASX in 2001. With a key collaboration with Isis Pharmaceuticals and license to Isis’ 2nd generation antisense inhibitor ATL1102 to CD49d, Dr Tachas has directed the expansion of the company pipeline. He is co-inventor of the growth hormone receptor antisense treatment for acromegaly, diabetic retinopathy, nephropathy and cancer, the IGF-IR antisense treatment for prostate cancer, the ATL1102 inhaled asthma treatment and the ATL1102 treatment for multiple sclerosis and stem cell mobilization.
Research Interest
Innovative, pragmatic affordable effective solutions to drug discovery, drug pipeline management, R&D management, intellectual property protection and licensing. Business development in start up biotech ventures and small biotherapeutic companies (20 employees).
